Major depressive disorder is a mood disorder marked by persistent depressive symptoms and clinically significant functional impairment. It is among the most common mental disorders and contributes substantial disability burden.
MRI-guided brain stimulation achieved 80% response rates for treatment-resistant depression versus 60% with conventional targeting, per a JAMA Psychiatry study. Separately, Barcelona researchers developed an MRI tool to accurately identify rare neurodegenerative tauopathies PSP and CBD, while experts in Paris discussed AI's growing role in predictive psychiatry.
Helus Pharma announced publication in Nature Medicine of Phase 2a trial results showing its short-acting psychedelic SPL026 met its primary endpoint with significant reductions in depressive symptoms at two weeks in moderate-to-severe MDD patients. The company also appointed a new SVP of Medical Affairs and is advancing HLP003 (Breakthrough Therapy Designation from FDA) and HLP004 in its pipeline.
Takeda Pharmaceutical Company has announced updates on two ongoing neuroscience clinical trials: a Phase 2 study of TAK-360 for narcolepsy and a Phase 3 study of vortioxetine for major depressive disorder in Japanese teens. Both trials are randomized, triple-blind, and currently recruiting patients.
Xenon Pharmaceuticals reported positive Phase III X-TOLE2 results for azetukalner in focal onset seizures. The company plans an FDA new drug application in Q3 2026.
Compass Pathways reported positive late-stage COMP360 psilocybin data in treatment-resistant depression and plans FDA talks ahead of a filing between October and December. The update lifted shares across several psychedelics developers.
New findings on psychedelic-based depression treatments included a UK DMT trial in 34 adults and a mouse study of modified psilocin compounds with fewer hallucinogenic-like effects.
A 34-person trial found that a single 21.5mg intravenous dose of DMT with psychotherapy produced rapid antidepressant effects lasting three to six months. Separate brain-scan research across five psychedelics found a shared pattern of weaker within-network links and stronger communication between brain networks.
Alzamend Neuro reports pharmacodynamic data showing AL001 may have a distinct brain interaction profile compared to lithium carbonate, with potential tolerability advantages. The Phase II trial analysis suggests AL001 affects key brain metabolites differently while maintaining lithium's core mechanism of action. Further confirmatory studies are planned to validate these initial findings.
Studies of psilocybin found lasting shifts in life values in healthy volunteers and reduced fear of death in therapeutic settings. Trials have also reported benefits in cancer patients.
Johnson & Johnson reported strong Q4 2025 earnings with $2.46 adjusted EPS and $24.56 billion in sales, beating estimates. The company faces over 67,000 active talc lawsuits following recent trial losses while projecting 2026 sales of $100-101 billion and maintaining a robust pipeline with recent FDA approvals and breakthrough designations.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07611487 |
Multimodal MRI Study of Acupuncture's Rapid Antidepressant Mechanisms and Response Prediction in Depression |
NOT_YET_RECRUITING | NA |
| NCT07596914 |
Multi-site Feasibility of an Integrated Treatment for the Biology and Experience of Depression: The MULTIBED Study |
NOT_YET_RECRUITING | NA |
| NCT07594483 |
Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium |
NOT_YET_RECRUITING | NA |
| NCT07592689 |
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) |
RECRUITING | PHASE3 |
| NCT07572526 |
tDCS: Sleep to Mood in Depression (S2M-D) |
NOT_YET_RECRUITING | NA |
| NCT07555743 |
Efficacy and Safety of Daridorexant in Patients With Major Depressive Disorder and Insomnia |
NOT_YET_RECRUITING | PHASE4 |
| NCT07554755 |
TIS for NSSI in Adolescent Depression |
RECRUITING | NA |
| NCT07534475 |
Venous Tourniquet vs. Arterial Tourniquet for Seizure Monitoring in ECT |
NOT_YET_RECRUITING | NA |
| NCT07528157 |
Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression |
NOT_YET_RECRUITING | NA |
| NCT07526454 |
Electroconvulsive Therapy Versus Intravenous Ketamine in Treatment-Resistant Major Depressive Disorder |
COMPLETED | NA |
